AstraZeneca's Brilinta fails in peripheral artery disease trial

LONDON (Reuters) - AstraZeneca said on Tuesday its heart drug Brilinta failed to show any benefit over an existing medicine in treating peripheral artery disease (PAD) in a large-scale clinical trial.